Fredrik Frejd, Chief Scientific Officer at Affibody, explains how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches. The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis' Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in 2024. This commercial validation has […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!